CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...